Martina Bernardi

Martina Bernardi

Auto-generated profile, based on publicly available information

Martina Bernardi

Haematology Unit, Laboratory of Advanced Cellular Therapies, San Bortolo Hospital, Vicenza, Italy

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2023 in Hematology
Verified
Journal Article
Open access
ABAngela Bozza
Angela Bozza
MBMartina Bernardi
Martina Bernardi
DCDaniela Catanzaro
Daniela Catanzaro
KCKatia Chieregato
Katia Chieregato
AMAnna Merlo
Anna Merlo
GAGiuseppe Astori
Giuseppe Astori
Polycythemia Vera (PV) is a myeloproliferative neoplasm characterized by the overproduction of red blood cells. First-line therapies are directed at lowering hematocrit levels. After the discovery ...

1 October 2018 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
DAD. Arpin
D. Arpin
MCM. Charpentier
M. Charpentier
MBM. Bernardi
M. Bernardi
ABA. Boni
A. Boni
EWE. Watkin
E. Watkin
DDD. Damotte
D. Damotte

8 April 2025 in Cytotherapy
Verified
Journal Article
Open access
Roberto TonelliRoberto Tonelli
Roberto Tonelli
FPFrancesca Pischiutta
Francesca Pischiutta
FEFrancesca Elice
Francesca Elice
EZElisa R Zanier
Elisa R Zanier
GGGiulia Grisendi
Giulia Grisendi
MDMassimo Dominici
Massimo Dominici
SARS-CoV-2 infection triggers respiratory inflammation with potentially fatal systemic effects. Mesenchymal stromal/stem cells (MSCs) are promising for treating severe COVID-19 due to their anti-inflammatory and regenerative capacities. This study investigates the effects of allogeneic MSCs in severe COVID-19 pneumonia. In the phase I/IIa RESCAT trial (May 2021-Feb 2022), patients with severe COVID-19 pneumonia received two intravenous MSC infusions and were compared to a control group (CTRL). To assess cytokine and biomarker responses, the MSC group was matched 1:2 with standard care patients (mCTRL) by age, gender, BMI, and PaO2/FiO2 (Nov 2020-Feb 2021). Random-effects linear regression evaluated cytokine and biomarker trends over time between MSC and control groups. Seventeen patients (MSC = 5, CTRL = 2, mCTRL = 10) were analyzed. Two MSC infusions were feasible and safe, with all patients discharged on average 15 ± 3.7 days postsecond infusion. While IL1RA and IL18 levels significantly increased in CTRL-mCTRL patients (P = 0.044 and P = 0.032), MSC treatment averted these rises, showing a distinct trajectory, particularly for IL1RA. MSC treatment also reduced IL6 levels compared to CTRL-mCTRL, while both groups showed similar reductions in Long pentraxin. Furthermore, MSC infusions prevented the neurofilament light chain surge observed in CTRL patients. MSC in COVID-19 patients resulted safe and feasible, effectively modulating inflammatory cytokines, in particular mitigating brain damage related biomarker, suggesting both reduced inflammation and a potential neurological protection.

1 April 2013 in Journal of Hepatology
Verified
Journal Article
Open access
FGF.A. Giannone
F.A. Giannone
MBMaurizio Baldassarre
Maurizio Baldassarre
MDMarco Domenicali
Marco Domenicali
LNL. Napoli
L. Napoli
MNMarina Naldi
Marina Naldi
PCPaolo Caraceni
Paolo Caraceni